The research team, led by Baohua Jiang and Ke Li of the People’s Hospital of Suzhou New District, began not in the animal facility but in the public data repositories. They downloaded the GSE128240 microarray dataset from the Gene Expression Omnibus, a database maintained by the National Center for Biotechnology Information, and used it to identify genes whose expression differs between healthy ovarian tissue and tissue affected by ovarian insufficiency. The analysis yielded 1,816 differentially expressed genes, a strikingly large molecular signature that underscores how profoundly ovarian failure remodels the transcriptome of the organ. Rather than treating these genes as an undifferentiated list, the investigators clustered them into co-expression modules and focused on the most significant ones, reasoning that genes acting together are more likely to represent genuine disease biology than isolated statistical hits.

To interpret the biology hidden in those modules, the team turned to two of the standard workhorses of computational genomics: Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes, known universally as GO and KEGG. These databases map individual genes onto curated biological processes, cellular components and signaling cascades, allowing researchers to ask whether a set of co-regulated genes is enriched for particular functions. In this case, the enrichment analyses pointed to two dominant themes. The first was the PI3K-Akt signaling pathway, a canonical survival cascade that promotes cell growth, metabolism and resistance to apoptotic signals, and which has previously been implicated in granulosa cell maintenance. The second was ovarian steroidogenesis, the enzymatic machinery by which the ovary converts cholesterol into estradiol and other sex steroids. Together, the two enriched categories suggested that ovarian failure involves both a loss of cell survival signaling and a collapse of the endocrine function that depends on healthy follicular cells.

With the bioinformatic roadmap in hand, the researchers moved to the experimental phase. They established a mouse model of premature ovarian failure by administering cyclophosphamide, a chemotherapy agent that preferentially damages proliferating granulosa cells and primordial follicles, thereby mimicking the gonadotoxicity seen in young cancer patients. Once the model was established, the mice received mouse bone marrow mesenchymal stem cells, or mBMSCs, over a four-week treatment period. Mesenchymal stem cells are multipotent stromal cells that can be isolated from bone marrow and expanded in culture; they are prized in regenerative medicine not primarily because they replace lost tissue, but because they secrete trophic and immunomodulatory factors that coax damaged environments toward repair. The four-week window was chosen to allow sufficient time for the cells to exert their paracrine effects on the injured ovary.

The results of the treatment were assessed on three complementary fronts: histology, endocrinology and molecular pathology. Hematoxylin-eosin staining of ovarian sections revealed that the stem cell-treated mice retained significantly more follicles than their chemotherapy-only counterparts, indicating that the treatment protected or restored the structural substrate of fertility. On the hormonal level, the picture was equally clear. Concentrations of estradiol, the primary estrogen produced by the ovary, rose significantly in the mBMSC-treated animals, while follicle-stimulating hormone and luteinizing hormone, the pituitary gonadotropins that rise in a compensatory fashion when the ovary fails, fell significantly. This hormonal shift is precisely what one would expect if the ovary had regained functional capacity: a healthier ovary produces more estrogen and requires less pituitary drive to do so.

The mechanistic heart of the study lies in what the researchers found when they probed the apoptotic machinery of the treated ovaries. Using Western blotting and immunohistochemistry, they measured the levels of three proteins that sit at the center of the intrinsic apoptosis pathway: Bcl-2, Bax and Caspase-3. Bcl-2 is an anti-apoptotic guardian that preserves mitochondrial integrity, while Bax is its pro-apoptotic antagonist, promoting mitochondrial outer membrane permeabilization and the release of cytochrome c. Caspase-3, often called the executioner caspase, is the protease that ultimately dismantles the cell once the apoptotic decision has been made. In the chemotherapy-treated mice, the balance tipped decisively toward cell death: Bax and Caspase-3 levels were significantly elevated in ovarian tissue, consistent with widespread granulosa cell apoptosis driving follicle depletion.

After four weeks of mBMSC treatment, that balance shifted back. Levels of Bax and Caspase-3, which had been significantly increased by cyclophosphamide, were significantly decreased following stem cell therapy, while the anti-apoptotic Bcl-2 axis was correspondingly reinforced. The authors conclude that mouse bone marrow mesenchymal stem cells attenuate apoptosis in chemotherapy-damaged ovaries by regulating the Bcl2/Caspase3 signaling pathway, and that this regulation is the mechanism through which the cells effectively treat premature ovarian failure in the model. In other words, the stem cells appear to act less as replacement oocytes or follicles and more as pharmacological agents in cellular form, reprogramming the death-versus-survival calculus of the remaining ovarian cells so that more follicles survive the toxic insult.

The significance of this mechanistic clarity should not be understated. Stem cell therapy for premature ovarian insufficiency has accumulated a substantial body of animal evidence over the past two decades, with studies reporting benefits from adipose-derived, amniotic, endometrial and embryonic stem cell-derived mesenchymal populations, sometimes delivered with collagen scaffolds or attributed to paracrine signaling. Meta-analyses of animal models and early human case reports have suggested genuine promise. But a recurring criticism has been that the field knows that stem cells help without knowing precisely how, which complicates the design of clinical trials, the selection of the optimal cell type and dose, and the identification of which patients are most likely to benefit. By anchoring the therapeutic effect to a specific, measurable molecular pathway, the Suzhou team has provided a target that future studies can manipulate directly, for example by testing whether drugs that mimic the Bcl-2-preserving effect could substitute for cell therapy in some settings.

The study also carries a cautionary relevance beyond reproductive medicine. Cyclophosphamide-induced ovarian failure is the laboratory mirror of a real clinical problem: breast cancer treatment, systemic lupus erythematosus therapy and other cyclophosphamide-based regimens place young women at substantial risk of fertility loss. Fertility preservation strategies such as oocyte or ovarian tissue cryopreservation help some patients, but they are invasive, expensive and not always feasible before urgent cancer treatment. A therapy that could be administered after chemotherapy to rescue remaining follicles would represent a fundamentally different and more accessible approach. The finding that the PI3K-Akt pathway and ovarian steroidogenesis were the dominant enriched functions in the disease transcriptome further suggests that multiple nodes of the survival machinery could be targeted in parallel, potentially combining stem cell paracrine effects with small-molecule pathway modulators.

As with all preclinical work, the distance between mice and women remains considerable. The study used mouse bone marrow mesenchymal stem cells in a mouse model, and human translation will require demonstrating that human cells, delivered safely and reproducibly, achieve comparable pathway modulation in human ovaries. Questions about the fate of the transplanted cells, the duration of the effect, the possibility of off-target effects on residual cancer risk, and the standardization of cell preparations all await answers. Nevertheless, the study offers something the field has needed: a coherent causal chain linking a defined cell type, a defined injury model and a defined molecular mechanism to a measurable restoration of endocrine and histological ovarian function. If that chain holds up in larger and more translational models, the humble mesenchymal stem cell, harvested from bone marrow and guided by the ancient logic of the Bcl2/Caspase3 switch, may yet become a meaningful option for women facing chemotherapy-induced ovarian failure.

Subject of Research: Mesenchymal stem cell therapy for chemotherapy-induced premature ovarian failure via the Bcl2/Caspase3 apoptosis pathway

Article Title: Mouse Bone Mesenchymal Stem Cells Attenuate Apoptosis by Regulating the Bcl2/Caspase3 Signaling Pathway in Premature Ovarian Failure

Article References: Jiang, B., Li, K., Zhang, L. L., Zhang, S. S., Wang, J. J., & Jin, L. (2026). Mouse Bone Mesenchymal Stem Cells Attenuate Apoptosis by Regulating the Bcl2/Caspase3 Signaling Pathway in Premature Ovarian Failure. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02094-8

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02094-8

Keywords: premature ovarian failure, mesenchymal stem cells, Bcl2/Caspase3, apoptosis, cyclophosphamide, ovarian reserve, PI3K-Akt pathway, steroidogenesis, follicles, fertility preservation, regenerative medicine, Reproductive Sciences

The significance of the study lies partly in the sheer ubiquity of the exposure. Fungal infections are among the most frequent ailments in pregnancy, driven by hormonal and immunological changes that alter the body’s microbial balance. They are typically treated with azole antifungals, a broad family of compounds that includes both prescription drugs and, crucially, over-the-counter topical products such as creams and vaginal tablets. As Gylli Mola, a researcher and medical doctor at Rigshospitalet, points out, this is what makes the result particularly noteworthy: the treatments in question were primarily non-prescription topical preparations, which have traditionally been regarded as safe to use during pregnancy. If even these low-intensity, locally applied formulations are associated with hormonal signals in offspring, the assumption of safety may need to be re-examined with more rigorous data than currently exists.

The study rested on an unusually broad evidentiary base. The researchers analysed data from 589 Danish mother–child pairs, drawing on Denmark’s rich national registers and biobanks to compare children whose mothers had used azole antifungals during pregnancy with those who had not. Crucially, the epidemiological signal did not stand alone. The team supplemented the population data with laboratory experiments using human fetal adrenal tissue, allowing them to observe directly how azole compounds interact with the steroid-producing machinery of the gland. They also carried out studies in pregnant rats, examining both blood and adrenal tissue from the fetuses to see whether the same hormonal disruptions appeared in a controlled experimental setting. According to Monica Kam Draskau, a researcher at the DTU National Food Institute who worked on the experimental analyses, the fact that the findings in children are supported by results from both human fetal adrenal tissue and rat experiments strengthens the hypothesis that there is a genuine link with the use of azole-based antifungal medicines.

To understand why the adrenal gland matters here, it helps to consider what azoles actually do. Azole antifungals work by inhibiting enzymes in the cytochrome P450 family that fungi need to build ergosterol, an essential component of their cell membranes. The trouble is that humans rely on closely related P450 enzymes to manufacture steroid hormones, including the cortisol and other adrenal steroids that the fetus begins producing as its adrenal gland develops. A compound designed to block fungal steroid synthesis can, in principle, also interfere with human steroidogenesis, and the fetal adrenal gland is an extraordinarily active steroid-producing organ during gestation. The new findings are consistent with that mechanism: prenatal exposure to azoles appears to disrupt fetal steroidogenesis, and the disruption seems to leave traces that persist at least into early infancy.

Adrenal hormones are far from peripheral players in human physiology. They help regulate many functions in the body, including glucose metabolism, blood pressure, immune function, and growth and reproductive development. The adrenal gland also undergoes a remarkable transformation around the time of birth, known as the zona reticularis transition, when the fetal zones of the gland regress and adult-type steroid production takes over. Hormonal disturbances during this window could, in theory, ripple across multiple organ systems as a child grows. That is precisely why the Danish team is cautious but concerned: the hormone levels they measured at three months of age were still within the normal range, yet the pattern of change suggests that fetal development may have been affected in ways that standard clinical thresholds do not capture.

Professor Terje Svingen from the DTU National Food Institute, who led the work, described the persistence of the signal as striking. It is one thing, he noted, for a medicine to produce a transient hormonal blip that resolves within days; it is quite another for the use of azole-based antifungals during pregnancy to appear to affect adrenal hormone levels in children long after birth. The three-month timepoint means the differences survived the profound hormonal upheaval of delivery and the establishment of infant adrenal function. Svingen’s framing captures the careful middle ground the study occupies: the results suggest that fetal development may have been affected, but they stop well short of demonstrating harm, and the researchers are explicit that they do not know whether the differences will affect the children’s health or their ability to have children later in life.

That caution is scientifically essential. The study is observational in its human component, and it cannot directly establish that azole-based antifungal medicines cause the hormonal changes observed in children. Mothers who used antifungals may differ in other ways from those who did not, from infection severity to other medication use, and no observational design can fully exclude such confounding. Nor can the researchers conclude from this study that commonly used antifungal medicines are harmful to children. What the results do is raise a hypothesis, supported by converging lines of evidence, that now needs to be tested with dedicated studies. The authors argue that the safety of widely used antifungals during pregnancy warrants further investigation, and the triangulation of human data, human tissue experiments and animal studies gives that argument unusual weight for a finding of this kind.

The research was carried out as part of the MERLON research project and was funded by the Danish Environmental Protection Agency through the Danish Centre on Endocrine Disrupters, with additional support from the Rigshospitalet Research Council. IRSET in France was a partner in the study. That funding provenance is telling: endocrine disruption, the interference of chemicals with the body’s hormone systems, has become a major focus of European regulatory science, and medicines are increasingly scrutinised alongside industrial chemicals for their potential to perturb hormonal development. The authors declare no conflicts of interest, and the study appeared under the title ‘Prenatal antifungal exposure disrupts fetal steroidogenesis and is associated with persistent effects in children’.

For pregnant women, the immediate practical message is one of reassurance rather than alarm. Untreated fungal infections carry their own risks, and no current evidence indicates that a course of azole treatment harms a child; the measured hormone levels in the study remained within normal limits. The researchers themselves stress that they cannot conclude the medicines are harmful. The appropriate response, they suggest, is not for women to avoid needed treatment but for regulators, clinicians and researchers to generate the data needed to confirm or refute the signal. Larger cohorts, longer follow-up of exposed children, and mechanistic work clarifying which azoles, doses and exposure windows matter most would all help determine whether the hormonal differences observed at three months of age are a transient footprint or a marker of lasting developmental change.

The study also speaks to a broader lesson in pharmacology and public health: medicines assumed to be safe because they are old, familiar and available without prescription are not automatically free of subtle developmental effects. Topical preparations deliver lower systemic doses than oral drugs, but pregnancy is a period of exquisite hormonal sensitivity, and the fetal adrenal gland is one of the most hormonally active tissues in the body. The Danish findings do not overturn clinical practice, but they add an important data point to the ongoing effort to make medication use in pregnancy evidence-based rather than assumption-based. Until that evidence matures, the study stands as a carefully hedged but consequential reminder that even the most routine treatments of pregnancy deserve continued scientific scrutiny.

Subject of Research: Effects of prenatal azole antifungal exposure on fetal steroidogenesis and infant adrenal hormone levels

Article Title: New study raises questions about antifungal treatments during pregnancy

Article References: New study raises questions about antifungal treatments during pregnancy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: azole antifungals, pregnancy, fetal development, adrenal hormones, steroidogenesis, endocrine disruption, Communications Medicine, DTU National Food Institute, Rigshospitalet, over-the-counter medicines, child health, pharmacovigilance

The construct, which the team calls SPHEGaT — spheroids of endocrine granulosa and theca cells — was built from primary human cells with careful attention to spatial organization. Granulosa cells, harvested from patients undergoing in vitro fertilization, expressed the aromatase enzyme CYP19A1 and the follicle-stimulating hormone receptor, marking them as the estrogen-producing core. Theca-like cells were differentiated from ovarian stromal cells isolated from postmenopausal donors, and they expressed CYP17A1 and CD13, consistent with their role in producing the androgens that granulosa cells then convert into estradiol. When the granulosa cells were seeded into low-attachment plates, they spontaneously self-aggregated into compact spheres within about three days. Theca-like cells were then added and progressively organized around the granulosa core, and a thin layer of collagen type I was deposited between the two compartments to mimic the follicular basement membrane. The result was a multilayered structure that echoes the compartmental arrangement of a native follicle.

Architecture, it turns out, is not merely cosmetic. After nine days of culture, the spheroids were remarkably healthy: quantitative analysis showed that 97.45 percent of the spheroid area remained viable, with no detectable focal necrosis. Dense three-dimensional aggregates often suffer from oxygen starvation in their cores, a problem the team checked directly by staining for HIF-2α, a marker of hypoxic stress. Only about 3 percent of nuclei were positive, and three-dimensional reconstruction confirmed the absence of a hypoxic core. Critically, the spheroids were functionally competent: the culture medium contained endogenous levels of estradiol at roughly 65 picograms per milliliter and progesterone at roughly 186 nanograms per milliliter. The spatially organized assembly had produced a living, breathing endocrine unit — one that secretes hormones the way a follicle does, rather than sitting passively in a bath of supplied steroids.

The decisive experiment came when the researchers coupled these spheroids to endometrial organoids, miniature gland-like structures grown from endometrial biopsies of women in their late twenties. Over six days of co-culture, the organoids underwent a visible transformation. Monocultured organoids retained mostly spherical, cyst-like shapes, but organoids exposed to the ovarian spheroids progressively developed folded, lobulated, and optically denser architectures. The proportion of folded organoids rose from about 2.4 percent in monoculture to nearly 13.7 percent in co-culture by day six, a highly significant difference. Circularity and solidity — geometric measures of how round and how smooth an organoid is — both declined over time in the co-cultured condition, indicating the emergence of irregular, invaginated epithelial structures reminiscent of glandular remodeling in the cycling endometrium.

What makes this remodeling striking is that it was not driven by proliferation. Ki67 staining, a standard marker of dividing cells, showed no significant difference between monocultured and co-cultured organoids, and total organoid area grew comparably in both conditions. The ovarian spheroids were not making the tissue grow faster; they were teaching it to reorganize. This mirrors in vivo physiology, where epithelial proliferation peaks during the estrogen-dominated proliferative phase and then stabilizes as progesterone steers the tissue toward secretory maturation. A trend toward reduced vimentin expression in co-cultured organoids further hinted at a dampening of epithelial-mesenchymal plasticity, a shift associated with secretory differentiation. In short, the ovarian signal was instructing architecture, not cell division.

At the molecular level, the co-culture produced clear evidence of endocrine reprogramming. Progesterone receptor expression surged in co-cultured organoids: only about 4.7 percent of nuclei were progesterone receptor-positive in monoculture, compared with roughly 40.5 percent after exposure to the spheroids. Estrogen receptor levels, by contrast, remained unchanged. The co-cultured organoids also upregulated a selective set of progesterone-responsive, secretory-phase genes, including PAEP, which encodes pregnancy-associated endometrial protein; SPP1, or secreted phosphoprotein 1; and HSD17B2, an enzyme involved in steroid metabolism. PAEP secretion, measured by ELISA, rose progressively in co-culture. Other receptivity-associated genes such as LIF, SOX17, GATA2, and AREG did not change significantly, indicating that the organoids entered a partial, progesterone-driven secretory state rather than acquiring the full implantation-window program — a limitation the authors attribute in part to the absence of an estrogen-priming phase in the current protocol.

One of the most intriguing observations was a hint of bidirectional communication. In the co-culture system, progesterone levels in the medium dropped markedly — to about 68 nanograms per milliliter compared with roughly 239 in spheroid monocultures — while estradiol levels stayed stable. This hormone-specific reduction suggests the endometrium may be actively metabolizing, taking up, or otherwise modulating ovarian progesterone output, echoing the known ability of uterine prostaglandins and other mediators to regulate luteal steroid production in vivo. The platform, in other words, does not just deliver hormones to the endometrium; it establishes a coupled endocrine axis in which hormone availability reflects ongoing integration between the two tissue compartments.

To test whether the morphogenic effects depended on steroids alone, the team performed an elegant depletion experiment. They treated spheroid-conditioned medium with dextran-coated charcoal, stripping out roughly 59 percent of the estradiol and 90 percent of the progesterone, and then compared three conditions: intact conditioned medium, depleted medium, and depleted medium with exogenous hormones added back. The results were unambiguous. Untreated conditioned medium induced the greatest epithelial folding over time. Depleted medium still supported a reduced but significant increase in folding — hinting at residual steroid activity or non-steroidal factors — but static hormone add-back failed entirely to restore the morphogenic phenotype and actually produced the lowest folding response of all. Organoids in the add-back condition grew larger but stayed smoother, suggesting that supraphysiologic or imbalanced steroid exposure biases tissue toward expansion rather than differentiation.

The implication is profound: the ovary’s instructive power over the endometrium cannot be reduced to a prescription of estradiol and progesterone. The intact follicle is a complex endocrine and paracrine factory, co-secreting inhibins and activins, growth factors such as EGF-like ligands and basic FGF, cytokines, metabolites, carrier proteins, and extracellular vesicles loaded with proteins, lipids, and regulatory RNAs. Many of these factors have been implicated in endometrial remodeling and implantation, and the temporal fluctuations, concentration gradients, and local metabolism inherent to an intact ovarian unit may be as important as any single molecule. Static hormone replacement, the study suggests, fundamentally cannot reproduce that context.

The researchers are candid about the limitations. The system models a progesterone-dominant environment without a preceding estrogen-priming phase, so it captures only part of the menstrual cycle’s proliferative-to-secretory transition. The co-culture lacks stromal decidualization, immune cells, vascular elements, and embryo-derived signals, all of which contribute to true uterine receptivity. The theca-like cells derive from postmenopausal donors, raising questions about age-related epigenetic carryover, and charcoal-dextran treatment may have altered non-steroidal components of the conditioned medium. Yet these caveats do not diminish the central achievement. The team has built the first spatially organized, fully human ovarian endocrine construct capable of directing endometrial morphogenesis in vitro, and shown that its effects exceed anything achievable with hormones alone. The platform opens a tractable window onto infertility, implantation failure, progesterone resistance, and endocrine disruption — and points toward a future generation of reproductive models built not on hormone recipes, but on reconstructed, talking tissues.

Subject of Research: Engineering spatially organized human ovarian spheroids to model ovarian-endometrial endocrine communication in vitro

Article Title: Spatially Organized Human Ovarian Spheroids Instruct Endometrial Morphogenesis

Article References: Sousa, M. J., Vriendt, S. D., Liu, L., Ruiz, T. F. R., Vankelecom, H., & Amorim, C. A. (2026). Spatially Organized Human Ovarian Spheroids Instruct Endometrial Morphogenesis. Advanced Science, 13(55), Article e76538. https://doi.org/10.1002/advs.76538

Image Credits: AI Generated

DOI: 10.1002/advs.76538

Keywords: ovarian spheroids, endometrial organoids, granulosa cells, theca-like cells, progesterone signaling, estradiol, steroidogenesis, reproductive biology, organ-on-a-chip, endometrial morphogenesis, infertility modeling, 3D cell culture

BPA, chemically known as 2,2-bis(4-hydroxyphenyl) propane, is a workhorse of industrial chemistry. It forms the backbone of polycarbonate plastics and epoxy resins and lurks in food packaging linings, metal cans, water bottles, electronic devices, toys, and medical equipment. Because its molecular structure features two phenolic rings resembling those of the hormone estradiol, BPA can mimic estrogenic activity in the body. The bonds holding BPA within polymerized resins are flexible enough that acidic or basic conditions and elevated temperatures liberate the compound, allowing it to migrate into food and drink. As a lipophilic molecule, it enters the body through mucous membranes, the respiratory tract, and skin, most often via the food chain.

The consequences of this ubiquitous exposure are far from trivial. BPA has been detected in breast milk, ovarian follicular fluid, amniotic fluid, umbilical cord blood, and placental tissues, indicating that humans are exposed from before birth onward. Research has linked the compound to elevated free radical production, disrupted meiosis, oocyte degeneration, and impaired ovarian function. The ovary is particularly vulnerable to oxidative stress, which can derail steroidogenesis, damage follicles, and degrade ovarian tissue. Prior studies have shown that BPA lowers estradiol levels, reduces the numbers of antral and primary follicles and corpora lutea, and promotes apoptotic changes in granulosa cells that may prevent ovulation altogether.

Enter quinoa, the Andean pseudocereal once revered as the mother of grains by the Incas and now celebrated globally as a superfood. Beyond its exceptional protein content and balanced amino acid profile, quinoa carries a pharmacological portfolio that includes antimicrobial, antioxidant, immunomodulatory, antidiabetic, neuroprotective, and hepatoprotective effects. Its seeds contain terpenoids, steroids, phenolic acids, and flavonoids with demonstrated anti-inflammatory, anticancer, and antidepressant potential. Earlier work had shown that quinoa seed powder could protect female rats against reproductive damage from the chemotherapy drug cisplatin, but no one had tested the seed extract against BPA-induced ovarian injury until now.

The research team, led by Pijus Kanti Jana and corresponding author Sandip Chattopadhyay, first characterized their hydroethanolic quinoa seed extract using liquid chromatography coupled with mass spectrometry. The analysis revealed four prominent phytochemical peaks: gallic acid, the most abundant compound at 170.76 mass-to-charge ratio, followed by caffeic acid, quercetin, and a 5-n-nonadecylresorcinol derivative. These molecules would prove central to the story, as each carries documented antioxidant, anti-inflammatory, or phytoestrogenic credentials that map neatly onto the damage pathways BPA exploits.

For the experiment itself, twenty-four virgin female Wistar albino rats, aged six to seven weeks, were randomly divided into four groups of six. Over twenty-eight consecutive days, the animals received daily oral gavage: a control group received olive oil alone, a positive control received quinoa ethanolic extract at 400 milligrams per kilogram of body weight, a BPA group received the chemical at 100 milligrams per kilogram, and a combined group received both BPA and the extract. The team monitored estrous cycles daily through vaginal smears, then on day twenty-nine collected serum and organs for an exhaustive battery of biochemical, molecular, and histological assays, all conducted under institutional ethics approval.

The results were striking across every measure. Rats exposed to BPA alone showed disrupted estrous cycles dominated by persistent metestrus and diestrus, significantly reduced serum estradiol and progesterone, diminished expression of the steroidogenic enzymes 3-beta-hydroxysteroid dehydrogenase and aromatase, and depleted estrogen receptor-alpha signaling. Their ovaries harbored arrested follicular growth and atretic follicles, and their relative ovarian weight dropped significantly. Antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase, were sharply suppressed, while lipid peroxidation markers malondialdehyde and conjugated dienes surged and lactate dehydrogenase leaked into the serum, a signature of cellular membrane damage and necrosis.

Coadministration of the quinoa extract reversed nearly all of this damage. Treated rats regained more regular estrous cycles, normalized hormone levels, and restored expression of ER-alpha, 3-beta-HSD, and aromatase. Antioxidant enzyme activity and expression rebounded, lipid peroxidation fell dramatically, and serum LDH declined, indicating protection from tissue necrosis. The inflammatory cascade also quieted: ovarian levels of TNF-alpha, NF-kappa-B, and IL-6, all significantly elevated by BPA, dropped toward baseline after quinoa supplementation. At the transcript level, BPA had boosted proapoptotic genes p53 and BAX while suppressing the antiapoptotic Bcl-2, an imbalance signaling cell cycle arrest and programmed cell death; quinoa co-treatment corrected this ratio. Under the microscope, ovaries from the combined group showed a predominance of normally developing follicles and far fewer atretic structures than the BPA-only group.

The authors attribute these protective effects to the specific phytochemicals identified in the extract. Quercetin, a phytoestrogen, can interact with estrogen receptors to improve estrogen and progesterone levels, while resorcinol engages helix 3 of ER-alpha through hydrogen bonding, exerting partial agonistic activity that helps restore estradiol signaling. On the antioxidant front, resorcinol activates Nrf2-mediated signaling, and gallic acid and quercetin raise cellular glutathione, scavenging reactive oxygen species before they can peroxidize cell membranes. Gallic acid also inhibits phosphorylation of I-kappa-B kinase, blocking NF-kappa-B nuclear translocation and the ensuing cytokine storm, while quercetin suppresses MAPK and downstream NF-kappa-B signaling and caffeic acid downregulates the TLR4/MyD88 pathway. Together, these molecules intercept BPA’s damage at the estrogenic, oxidative, inflammatory, and apoptotic levels simultaneously.

The researchers caution that this is a preliminary in vivo study in rats, and the doses involved, particularly the 100 milligrams per kilogram BPA exposure, far exceed typical human intake. Translating these findings into dietary recommendations for women will require dose-ranging work, pharmacokinetic data, and ultimately human studies. Still, the concept is tantalizing: a widely available, nutrient-dense seed whose bioactive compounds appear to fortify the ovary against one of the most pervasive contaminants of the industrial age. As concerns over endocrine disruptors continue to mount, quinoa’s journey from ancient Incan staple to potential protective nutraceutical offers a vivid reminder that sometimes the tools for fighting modern chemical hazards may have been growing in the Andes all along.

Subject of Research: Protective effects of quinoa seed extract against bisphenol A-induced ovarian toxicity in female rats

Article Title: Exploring the protective effects of ethanolic extract of Chenopodium quinoa seed (quinoa) on the reproductive alterations of BPA-exposed females in vivo: a preliminary study

Article References: Jana, P. K., Sil, S., Ghosh, A., Sultana, I., & Chattopadhyay, S. (2025). Exploring the protective effects of ethanolic extract of Chenopodium quinoa seed (quinoa) on the reproductive alterations of BPA-exposed females in vivo: a preliminary study. Discover Toxicology, 2(1), Article 7. https://doi.org/10.1007/s44339-025-00023-z

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00023-z

Keywords: bisphenol A, quinoa, ovarian toxicity, endocrine disruptors, oxidative stress, phytoestrogens, gallic acid, quercetin, reproductive health, antioxidants, Wistar rats, steroidogenesis

The research, conducted by an international team of investigators, presents a comprehensive comparative resource for adult human and mouse adrenal glands built on two complementary technologies: single-cell transcriptomics, which profiles the gene activity of thousands of individual cells, and spatial transcriptomics, which maps where those gene-expression programs reside within the intact architecture of the organ. By combining these approaches, the authors have produced what is effectively a high-resolution atlas of the adrenal gland in two species, capturing not only which cell types exist but also how their molecular identities and locations differ between human and mouse.

The significance of this resource lies in what it corrects. The adrenal cortex, the outer layer of the gland, is organized into zones that produce different classes of steroid hormones. In the classical textbook model, mineralocorticoids such as aldosterone are produced in the outermost zone, glucocorticoids such as cortisol in the middle zone, and androgen precursors in the innermost zone. This zonal model was largely established through work in rodents. The new single-cell and spatial data confirm that while broad zonal logic exists in both species, the underlying cellular states, the repertoire of expressed enzymes and the dynamics of cell differentiation diverge substantially between human and mouse, meaning that findings in mice cannot be assumed to apply directly to human adrenal physiology.

One of the study’s central findings concerns steroidogenic states. Steroid-producing cells do not represent a single, fixed identity; instead, they occupy a spectrum of molecular states defined by which steroidogenic enzymes they express, at what levels, and in what combinations. The comparative analysis shows that these states are shaped by species-specific programs. Human adrenal cells display enzymatic configurations and regulatory signatures that differ from their mouse counterparts in ways that affect how hormone synthesis is partitioned across the gland. For researchers studying disorders such as congenital adrenal hyperplasia, adrenal insufficiency, Cushing’s syndrome and primary aldosteronism, this is a critical caveat: therapeutic strategies validated in mouse models may engage cellular programs that human adrenal tissue either lacks or deploys differently.

The second major theme of the study is tissue turnover. The adrenal cortex is one of the most dynamic organs in the body, with its steroid-producing cells continuously replaced throughout life. The prevailing model, again derived largely from rodent studies, holds that a cap of progenitor cells near the outer surface of the gland continuously generates new steroidogenic cells that migrate inward, mature, perform their hormonal duties and eventually die, a conveyor-belt-like process of renewal. The new human data reveal that this turnover process, while conceptually conserved, proceeds with species-specific characteristics. The cellular sources of renewal, the differentiation trajectories and the pace of cell replacement differ between human and mouse, underscoring that the mouse conveyor-belt model is an approximation rather than a faithful replica of human adrenal maintenance.

Technically, the study’s strength comes from its dual-method design. Single-cell RNA sequencing excels at resolving cellular heterogeneity, distinguishing rare cell populations and reconstructing differentiation trajectories from the gene-expression fingerprints of individual cells. But dissociating an organ into single cells destroys spatial context, which is essential in an organ as architecturally organized as the adrenal gland. Spatial transcriptomics restores that context by measuring gene activity in intact tissue sections, allowing the researchers to verify that the cell states identified in the single-cell data occupy coherent anatomical positions. By applying both methods in parallel to human and mouse adrenal glands, the team could cross-validate cell-type assignments and map species differences with confidence, producing a resource designed to serve as a reference standard for the field.

The comparative framing also carries implications for regenerative medicine and drug development. Efforts to grow functional adrenal tissue in the laboratory, whether from stem cells or organoid cultures, depend on knowing which molecular programs must be activated to generate authentic steroid-producing cells. If those programs are species-specific, protocols optimized against mouse reference data may steer human cells toward the wrong developmental endpoints. Conversely, a human adrenal atlas provides a benchmark against which laboratory-grown adrenal cells can be quality-controlled, accelerating the path toward cell-based therapies for patients whose adrenal glands no longer function.

The resource is also expected to inform cancer research. Adrenocortical carcinoma is a rare but aggressive malignancy with limited treatment options, and its cellular origins remain incompletely understood. A detailed map of normal adrenal cell states in humans, including the progenitor populations and differentiation intermediates that tumors may hijack, offers researchers a framework for identifying which programs are reactivated in cancer and for designing therapies that target tumor-specific vulnerabilities while sparing normal steroid production.

Beyond disease, the study speaks to a broader lesson in modern biology: organ-level conclusions drawn from one species do not automatically transfer to another, even for organs as structurally similar as human and mouse adrenals. Evolution has conserved the gland’s essential function, the synthesis of life-sustaining steroids, but has implemented that function through partly divergent cellular and molecular means. As single-cell atlases accumulate across tissues and species, this theme recurs, and the adrenal gland now stands as a particularly clear example because its physiology is so directly tied to clinically essential hormones.

The authors have made their comparative dataset available as a community resource, allowing endocrinologists, developmental biologists and computational scientists to query cell-type markers, explore spatial gene-expression patterns and test their own hypotheses against the data. In an era when mouse models remain indispensable but increasingly scrutinized, resources of this kind provide the translational bridge that the field needs: a way to know precisely where the mouse is a faithful model of human biology, and where it is not. For the adrenal gland, at least, the answer is now written cell by cell, and it is more species-specific than anyone had fully appreciated.

Subject of Research: Comparative single-cell and spatial transcriptomic analysis of adult human and mouse adrenal glands

Article Title: Human and mouse adrenal glands are characterized by species-specific steroidogenic states and tissue turnover

Article References: Kastriti, M. E., Maksimov, D., Krupinova, J., Utkina, M., Beltsevich, D., Roslyakova, A., Glazova, O., Kaziakhmedova, S., Ryabova, A., Kuznetsova, A., Shcherbakova, A., Bondarenko, E., Antysheva, Z., Albert, E., Urusova, L., Lapshina, A., Chevais, A., Avsievich, E., Trofimov, V., … Adameyko, I. (2026). Human and mouse adrenal glands are characterized by species-specific steroidogenic states and tissue turnover. Nature Genetics, 58(9), 2270-2283. https://doi.org/10.1038/s41588-026-02737-1

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02737-1

Keywords: adrenal gland, single-cell transcriptomics, spatial transcriptomics, steroidogenesis, tissue turnover, human-mouse comparison, adrenal cortex, hormone production, cell atlas, Nature Genetics, endocrinology, regenerative medicine